Adam D. Cohen, MD

Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.

Asked about the biggest misconception community providers hold about the referral process, Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham Cancer Institute, emphasized that CAR T-cell therapy is a co-management strategy.

Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham Cancer Institute, asked what practical steps referring oncologists can take and what an ideal interaction with an academic medical center looks like.

Adam D. Cohen, MD, director of Myeloma Immunotherapy and professor of medicine at the Hospital of the University of Pennsylvania, asked whether patients lose the chance to receive CAR T-cell therapy if referral comes too late.

Adam D. Cohen, MD, reviews 5-year data from cohort A of CARTITUDE-2 for cilta-cel and how bridging therapy may lower the risk of late neurotoxicity.

With both CAR T-cell therapy and bispecific antibodies now available in early relapse, Adam D. Cohen, MD, director of Myeloma Immunotherapy and professor of medicine at the Hospital of the University of Pennsylvania, asked how clinicians should decide which modality comes first.

Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early relapsed multiple myeloma.

Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham Cancer Institute, explained that some toxicities of CAR T-cell therapy emerge within the first 30 days, while others can appear 90 days or later after infusion.

Adam D. Cohen, MD, said that more data are necessary to help determine how cevostamab can be sequenced with other T-cell–directed therapies.

Adam D. Cohen, MD, says patients with deep responses to cevostamab could stop therapy and stay in remission for years.

Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.

Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.